SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Emily Dickinson — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEmily Dickinson
Date of birth1830-12-10
IdentifiersMRN HR-NI023-SYN-TD; SSN (made up) 000-23-6081
Document date1885-09-28
AuthorLucinda Hartwell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Video visit for the six-month kidney review. [S]

History of Present Illness

Ms. Dickinson is seen by video from her home; the mobile phlebotomy service drew blood and collected a urine sample this morning, and she measured her vital signs with her own devices before the call. She feels well, with no headaches since the spring. Her home blood pressure averages 118/72. She takes losartan 100 mg, dapagliflozin 10 mg, amlodipine 5 mg, atorvastatin 20 mg, and vitamin D3 daily and has taken no NSAIDs. She has had no lightheadedness, ankle swelling, urinary symptoms, or muscle aches. She would like her second hepatitis B dose and her influenza vaccine at her preventive visit next month, so that she makes one trip. [S]

ElementDetail
Visit formatVideo visit from home, with home-measured vital signs and a home blood and urine collection
SymptomsNo headaches since the spring
Home blood pressureAverage 118/72 mmHg
Medication toleranceNo lightheadedness, edema, urinary symptoms, or muscle aches

Review of Systems

SystemResultFinding
CardiovascularNegativeNo ankle swelling or lightheadedness
GenitourinaryNegativeNo urinary symptoms or genital itching
NeurologicalNegativeNo headaches

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter)Two tablets as needed, up to twice a dayOral route1884-10-01 to 1885-01-12stoppedS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-01-12 to 1885-02-02completedS
Losartan 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-02-02activeS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-01-12activeS
Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-01-12activeS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as needed; maximum 6 tablets a dayOral route1885-01-12activeS
Dapagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-02-02activeS
Amlodipine 5 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-03-02activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1885-09-28Body height163cmS
1885-09-28Body weight53.4kgS
1885-09-28Body mass index (BMI) [Ratio]20.1kg/m2S
1885-09-28Systolic blood pressure118mm[Hg]S
1885-09-28Diastolic blood pressure74mm[Hg]S
1885-09-28Heart rate68/minS
1885-09-28Respiratory rate14/minS
1885-09-28Body temperature36.5CelS
1885-09-28Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1885-09-28Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1885-09-28Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
1885-09-28Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
1885-09-28Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL6-21 mg/dLNormalS
1885-09-28Creatinine [Mass/volume] in Serum or Plasma1.28mg/dL0.59-1.04 mg/dLHighS
1885-09-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M50mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
1885-09-28Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
1885-09-28Albumin/Creatinine [Mass Ratio] in Urine96mg/g<=30 mg/gHighS
1885-09-28Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
1885-09-28Phosphate [Mass/volume] in Serum or Plasma3.6mg/dL2.5-4.5 mg/dLNormalS
1885-09-28Parathyrin.intact [Mass/volume] in Serum or Plasma61pg/mL15-65 pg/mLNormalS
1885-09-2825-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma36ng/mL30-100 ng/mLNormalS

Physical Exam

Vital signs recorded on 1885-09-28; see the Vital Signs section. [S]

SystemFinding
General (video)Well and animated; respiratory rate 14 counted on video
Extremities (video)No pitting seen when she pressed on her shins
Mental status (video)Alert and engaged; euthymic

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificateactiveconfirmed N18.31S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists.
Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertensionactiveconfirmed I12.9S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists.
Vitamin D deficiency with a mildly raised PTH in chronic kidney diseaseactiveconfirmed E55.9S — Synthetic laboratory finding at the intake visit.
Viral gastroenteritis with volume depletion and a prerenal rise in creatinine while taking losartan and dapagliflozin; resolvedresolvedconfirmed A08.4S — Synthetic illness at an unscheduled home visit, chosen to teach sick-day rules in chronic kidney disease; it does not echo any documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryeGFR with metabolic panelTwice a year at G3a A2 (KDIGO heat map)Completed todayPotassium 4.6 mmol/L, creatinine 1.28 mg/dL, eGFR 50
LaboratoryUrine albumin-creatinine ratioTwice a year at G3a A2 (KDIGO heat map)Completed today96 mg/g, down from 240 at intake
LaboratoryCalcium, phosphate, and PTHEvery 6 to 12 months at G3aCompleted todayCalcium 9.4 mg/dL, phosphate 3.6 mg/dL, PTH 61 pg/mL
Laboratory25-hydroxyvitamin D after repletionAt baseline; repeated according to level and treatmentCompleted today36 ng/mL on vitamin D3
ExaminationStandardized home blood pressure on a validated cuffEvery visitCompleted today118/74 mmHg today; home average 118/72
ExaminationWeightEvery visitCompleted today53.4 kg on her home scale
ExaminationCardiac auscultationEvery visitDeferredNot possible at a video visit; no cardiac symptoms. Done at the June home visit and planned at next month's preventive visit
ExaminationFundoscopic examinationYearly in chronic hypertensionDuePlanned at next month's preventive visit
LaboratoryHemoglobin and KFREYearly in G3Up to dateHemoglobin 12.3 g/dL and KFRE 0.5 and 1.6 percent in January; due again in January
LaboratoryLipid panelOnce at diagnosis (KDIGO); yearly in the CMID hypertension scheduleNot indicatedOn atorvastatin for chronic kidney disease; KDIGO advises no routine repeat lipid testing
Medication safetyMedication review: NSAID avoidance, SGLT2 inhibitor and statin safetyEvery visitCompleted todayNo NSAIDs; no genital, urinary, or muscle symptoms
Medication safetyVaccination reviewYearly in chronic kidney diseaseDueHepB-CpG dose 2, influenza, and zoster dose 1 planned at next month's preventive visit, at her request, to avoid an extra trip; dose 2 remains well within the schedule
Self-managementSodium, activity, and home readingsEvery visitCompleted todayLow-salt cooking; garden work most afternoons

Goal progress:

Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026)

Follow-up: Preventive visit at the clinic next month. Yearly kidney tests and review in January. Next scheduled visit 1885-10-19: periodic adult preventive visit. [S]